Clinical Trial

A Prospective, Multicenter Clinical Study of Hetrombopag in the Prevention of Thrombocytopenia Caused by Lung Cancer Therapy

Name: A Prospective, Multicenter Clinical Study of Hetrombopag in the Prevention of Thrombocytopenia Caused by Lung Cancer Therapy — clinical trial record (NCT07101627)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

To evaluate the efficacy and safety of Hetrombopag in secondary prevention of thrombocytopenia caused by lung cancer treatment

Trial Details

NCT Number	NCT07101627
Lead Sponsor	Shanghai Pulmonary Hospital, Shanghai, China Collaborators: Jiangsu HengRui Medicine Co., Ltd.
Conditions	Lung Cancer
Enrollment	149 participants
Start Date	2025-08-01
Primary Completion	2027-04-30 (estimated)
Study Completion	2027-06-30 (estimated)
Updated on ClinicalTrials.gov	2025-08-03